BACKGROUND: Antipig antibodies are a barrier to clinical xenotransplantation. We evaluated antibody binding of waitlisted renal transplant patients to 3 glycan knockout (KO) pig cells and class I swine leukocyte antigens (SLA). METHODS: Peripheral blood mononuclear cells from SLA identical wild type (WT), α1, 3-galactosyltransferase (GGTA1) KO, GGTA1/ cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) KO, and GGTA1/ CMAH /b1,4 N-acetylgalactosaminyl transferase (B4GalNT2) KO pigs were screened for human antibody binding using flow cytometric crossmatch (FCXM). Sera from 820 patients were screened on GGTA1/CMAH/B4GalNT2 KO cells and a subset with elevated binding was evaluated further. FCXM was performed on SLA intact cells and GGTA1/SLA class I KO cells after depletion with WT pig RBCs to remove cell surface reactive antibodies, but leave SLA antibodies. Lastly, human and pig reactive antibodies were eluted and tested for cross-species binding and reactivity to single-antigen HLA beads. RESULTS: Sequential glycan KO modifications significantly reduce antibody binding of waitlisted patients. Sera exhibiting elevated binding without reduction after depletion with WT RBCs demonstrate reduced binding to SLA class I KO cells. Human IgG, eluted from human and pig peripheral blood mononuclear cells, interacted across species and bound single-antigen HLA beads in common epitope-restricted patterns. CONCLUSIONS: Many waitlisted patients have minimal xenoreactive antibody binding to the triple KO pig, but some HLA antibodies in sensitized patients cross-react with class I SLA. SLA class I is a target for genome editing in xenotransplantation.
BACKGROUND: Antipig antibodies are a barrier to clinical xenotransplantation. We evaluated antibody binding of waitlisted renal transplant patients to 3 glycan knockout (KO) pig cells and class I swine leukocyte antigens (SLA). METHODS: Peripheral blood mononuclear cells from SLA identical wild type (WT), α1, 3-galactosyltransferase (GGTA1) KO, GGTA1/ cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) KO, and GGTA1/ CMAH /b1,4 N-acetylgalactosaminyl transferase (B4GalNT2) KO pigs were screened for human antibody binding using flow cytometric crossmatch (FCXM). Sera from 820 patients were screened on GGTA1/CMAH/B4GalNT2 KO cells and a subset with elevated binding was evaluated further. FCXM was performed on SLA intact cells and GGTA1/SLA class I KO cells after depletion with WT pig RBCs to remove cell surface reactive antibodies, but leave SLA antibodies. Lastly, human and pig reactive antibodies were eluted and tested for cross-species binding and reactivity to single-antigen HLA beads. RESULTS: Sequential glycan KO modifications significantly reduce antibody binding of waitlisted patients. Sera exhibiting elevated binding without reduction after depletion with WT RBCs demonstrate reduced binding to SLA class I KO cells. Human IgG, eluted from human and pig peripheral blood mononuclear cells, interacted across species and bound single-antigen HLA beads in common epitope-restricted patterns. CONCLUSIONS: Many waitlisted patients have minimal xenoreactive antibody binding to the triple KO pig, but some HLA antibodies in sensitized patients cross-react with class I SLA. SLA class I is a target for genome editing in xenotransplantation.
Authors: C Burlak; L L Paris; A J Lutz; R A Sidner; J Estrada; P Li; M Tector; A J Tector Journal: Am J Transplant Date: 2014-06-06 Impact factor: 8.086
Authors: Hidetaka Hara; Mohamed Ezzelarab; Pleunie P M Rood; Yih Jyh Lin; Jamie Busch; Zuhaib Ibrahim; Xiaocheng Zhu; Suyapa Ball; David Ayares; Adriana Zeevi; Michel Awwad; David K C Cooper Journal: Xenotransplantation Date: 2006-07 Impact factor: 3.907
Authors: Arend Mulder; Marrie J Kardol; J Scott Arn; Chantal Eijsink; Marry E I Franke; Geziena M T Schreuder; Geert W Haasnoot; Ilias I N Doxiadis; David H Sachs; Douglas M Smith; Frans H J Claas Journal: Mol Immunol Date: 2009-11-22 Impact factor: 4.407
Authors: Ping Li; Jose L Estrada; Christopher Burlak; Jessica Montgomery; James R Butler; Rafael M Santos; Zheng-Yu Wang; Leela L Paris; Ross L Blankenship; Susan M Downey; Matthew Tector; A Joseph Tector Journal: Xenotransplantation Date: 2014-09-02 Impact factor: 3.907
Authors: Gertie J Oostingh; Hugh F S Davies; Kerrie C G Tang; J Andrew Bradley; Craig J Taylor Journal: Am J Transplant Date: 2002-03 Impact factor: 8.086
Authors: Qi Li; Hidetaka Hara; Zhongqiang Zhang; Michael E Breimer; Yi Wang; David K C Cooper Journal: Xenotransplantation Date: 2018-04-14 Impact factor: 3.907
Authors: Joseph M Ladowski; Luz M Reyes; Gregory R Martens; James R Butler; Zheng-Yu Wang; Devin E Eckhoff; Matthew Tector; A Joseph Tector Journal: Transplantation Date: 2018-02 Impact factor: 4.939
Authors: Joseph M Ladowski; Gregory R Martens; Luz M Reyes; Zheng-Yu Wang; Devin E Eckhoff; Vera Hauptfeld-Dolejsek; Matt Tector; A Joseph Tector Journal: J Immunol Date: 2018-03-14 Impact factor: 5.422
Authors: Hironosuke Watanabe; Yuichi Ariyoshi; Thomas Pomposelli; Kazuhiro Takeuchi; Dilrukshi K Ekanayake-Alper; Lennan K Boyd; Scott J Arn; Hisashi Sahara; Akira Shimizu; David Ayares; Marc I Lorber; Megan Sykes; David H Sachs; Kazuhiko Yamada Journal: Xenotransplantation Date: 2019-09-23 Impact factor: 3.907